Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

21.03USD
12 Dec 2017
Change (% chg)

$-0.59 (-2.73%)
Prev Close
$21.62
Open
$21.47
Day's High
$21.47
Day's Low
$19.93
Volume
97,572
Avg. Vol
75,395
52-wk High
$28.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

05 Dec 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

07 Nov 2017

BRIEF-Xencor Q2 loss per share $0.15

* Qtrly earnings per share $0.15 Source text for Eikon: Further company coverage:

07 Aug 2017

BRIEF-Xencor reports interim positive data from ongoing mid-stage study of XMAB5871

* Xencor presents interim data from an ongoing, open-label, phase 2 study of xmab®5871 in igg4-related disease at eular 2017

16 Jun 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.69 +0.12
Novartis AG (NOVN.S) CHF83.85 +0.30
Roche Holding Ltd. (ROG.S) CHF241.60 -0.10
Roche Holding Ltd. (RO.S) CHF243.90 -0.10
AstraZeneca plc (AZN.L) 4,925.00 -10.00
GlaxoSmithKline plc (GSK.L) 1,315.00 +0.50
AbbVie Inc (ABBV.N) $98.16 +1.86
Bristol-Myers Squibb Co (BMY.N) $63.48 +0.20
Bristol-Myers Squibb Co (BMYMP.PK) $1,060.00 +4.55
Amgen, Inc. (AMGN.OQ) $177.38 +1.12

Earnings vs. Estimates